Biological Response Modifier Therapy for Head and Neck Cancer.

スポンサーリンク

概要

• 論文の詳細を見る

• One of the important factors in improving the prognosis of head and neck cancer patients treated with combined therapy is the enhancement of the immunological response of the patients.Biological Response Modifiers (BRM) are expected to increase this response in cancer patients by augmenting host defence mechanisms. A comparative study was performed on patients with head and neck cancer, who received primary therapy, to evaluate the clinical effectiveness of BRM (lentinan). Twenty two patients were injected intravenously with 2mg of lentinan once a week (lentinan group).A control group of 23 patients received no lentinan therapy. The clinical effectiveness of lentinan therapy was verified by significant improvements in some of the immune responses. Natural killer cell activity and phytohemagglutinin biogenesis were increased, and immunosuppressive acidic protein and squamous cell carcinoma related antigen were decreased in the lentinan group.Prolongation of the life span occurred in advanced stage III and stage N patients.These results suggest that lentinan therapy is useful to some extent in the treatment of patients with head and neck cancer.

• 耳鼻咽喉科臨床学会の論文

著者

• 奥平 唯雄

  東京医科大学耳鼻咽喉科学教室

• 奥平 唯雄

  東京医科大学咽喉科学教室

関連論文

• 喉頭癌に対する光線力学的療法の臨床的検討
• 頭頸部癌に対する光線力学的療法の臨床応用
• 下咽討頸部食道癌の局所再発の臨床的検討
• 頸部 Castleman リンパ腫症例 免疫学的検討
• Biological Response Modifier Therapy for Head and Neck Cancer.
• Cystic lesions of paranasal sinus with eye symptoms.

スポンサーリンク